The first 60 days: Polycythaemia vera (PV)
Polycythaemia vera is a slow blood cancer in which a single faulty gene, JAK2, makes the bone marrow produce too many red cells. Thick blood causes clots, so treatment thins it (blood removal, aspirin) and, for higher-risk patients, calms the marrow with hydroxyurea, interferon or ruxolitinib; a hepcidin mimic, rusfertide, now controls red cell counts without regular blood removal. Below, week by week, is what OnCo's record of Polycythaemia vera (PV) says about the first two months: the order is typical, the timing is yours to ask about. Sections appear only where the record has something to say. Orientation, not medical advice.
What happens now
Staging tests establish exactly what and where the cancer is. Everything else follows from the answers.
Full blood count, JAK2 V617F and exon 12 testing, serum erythropoietin, and bone marrow biopsy showing trilineage growth; WHO criteria (haemoglobin above 16.5 g/dL in men or 16.0 in women, or haematocrit above 49 or 48 percent). Secondary causes of a high red count (smoking, sleep apnoea, kidney or liver tumours, testosterone) are excluded first.
Ask which of these were tested and what the results were; see the report reader for what each value means.
These specialties appear in the standard of care for this cancer. In most centres they meet weekly as a tumour board to agree each plan; you can ask when yours was discussed and what was decided.
- PathologistNamed in the standard of care for: Diagnosis.
- Medical oncologistNamed in the standard of care for: All patients, Low risk (under 60, no prior clot), High risk (over 60 or prior clot), Hydroxyurea resistance or intolerance and 2 more.
- Transplant and cell therapy teamNamed in the standard of care for: Hydroxyurea resistance or intolerance, Post-PV myelofibrosis.
A second opinion from a centre that treats many similar cases is normal, not rude; the standard of care tells you what to compare it against.
Each row is a setting from the standard of care, in the order it usually arises. Not all will apply to you; your stage and biomarkers decide which do. The guideline grade, where recorded, says how strong the evidence is.
Aspirin and phlebotomy alone; ropeginterferon alfa-2b is an option when phlebotomy is poorly tolerated or symptoms persist (Low-PV).
Add cytoreduction: hydroxyurea, or ropeginterferon alfa-2b (PROUD-PV and CONTINUATION-PV), the latter preferred in younger patients and in pregnancy.
Low-dose aspirin unless contraindicated, phlebotomy to a haematocrit under 45 percent (CYTO-PV), and control of cardiovascular risk factors.
Rusfertide, a hepcidin mimetic given by weekly injection, keeps the haematocrit under 45 percent and removes the need for phlebotomy in most patients (VERIFY).
Antihistamines, aspirin for erythromelalgia, interferon or ruxolitinib for severe aquagenic pruritus.
Managed as myelofibrosis: JAK inhibitors for spleen and symptoms, momelotinib for anaemia, allogeneic stem cell transplant for fit higher-risk patients.
Ruxolitinib (RESPONSE, RESPONSE-2, MAJIC-PV) for haematocrit control, spleen shrinkage and symptom relief; interferon if not already tried.
Generated from this cancer's standard of care, biomarkers and open problems. Take the group that matches where you are. To tick, add your own and print, open the one-page appointment sheet.
Newly diagnosed
- What is my exact diagnosis, stage, and grade, and which tests established them?Everything else follows from an accurate stage and subtype.
- Which biomarkers have been tested on my tumour (for example JAK2 V617F allele burden, JAK2 exon 12 mutations, Haematocrit, with treatment targeting below 45 percent, Serum erythropoietin, Leukocyte count above 11 x 10^9/L), and what were the results?These results decide eligibility for targeted therapy, immunotherapy, and trials.
- Which subtype is my cancer, and does that change the recommended treatment?Recognised subtypes for this cancer include JAK2 V617F-positive, JAK2 exon 12-mutated, Masked PV.
- Is germline (inherited) genetic testing recommended for me or my family?Inherited variants can change treatment and matter for relatives.
Diagnosis
- For my situation (diagnosis), which of the standard options do you recommend and why?Guideline options include: Full blood count, JAK2 V617F and exon 12 testing, serum erythropoietin, and bone marrow biopsy showing trilineage growth; WHO criteria (haemoglobin above 16.5 g/dL in men or 16.0 in women, or haematocrit above 49 or 48 percent). Secondary causes of a high red count (smoking, sleep apnoea, kidney or liver tumours, testosterone) are excluded first.
All patients
- For my situation (all patients), which of the standard options do you recommend and why?Guideline options include: Low-dose aspirin unless contraindicated, phlebotomy to a haematocrit under 45 percent (CYTO-PV), and control of cardiovascular risk factors.
- Am I a candidate for Aspirin, and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
- How do the results of CYTO-PV apply to someone like me?Trial populations differ from individual patients; ask how closely you match.
Low risk (under 60, no prior clot)
- For my situation (low risk (under 60, no prior clot)), which of the standard options do you recommend and why?Guideline options include: Aspirin and phlebotomy alone; ropeginterferon alfa-2b is an option when phlebotomy is poorly tolerated or symptoms persist (Low-PV).
- Am I a candidate for Ropeginterferon alfa-2b, and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
- How do the results of Low-PV apply to someone like me?Trial populations differ from individual patients; ask how closely you match.
High risk (over 60 or prior clot)
- For my situation (high risk (over 60 or prior clot)), which of the standard options do you recommend and why?Guideline options include: Add cytoreduction: hydroxyurea, or ropeginterferon alfa-2b (PROUD-PV and CONTINUATION-PV), the latter preferred in younger patients and in pregnancy.
- Am I a candidate for Hydroxyurea (hydroxycarbamide), Ropeginterferon alfa-2b, and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
- How do the results of PROUD-PV and CONTINUATION-PV apply to someone like me?Trial populations differ from individual patients; ask how closely you match.
Hydroxyurea resistance or intolerance
- For my situation (hydroxyurea resistance or intolerance), which of the standard options do you recommend and why?Guideline options include: Ruxolitinib (RESPONSE, RESPONSE-2, MAJIC-PV) for haematocrit control, spleen shrinkage and symptom relief; interferon if not already tried.
- Am I a candidate for Ruxolitinib, and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
- How do the results of RESPONSE and RESPONSE-2 apply to someone like me?Trial populations differ from individual patients; ask how closely you match.
Phlebotomy-dependent disease
- For my situation (phlebotomy-dependent disease), which of the standard options do you recommend and why?Guideline options include: Rusfertide, a hepcidin mimetic given by weekly injection, keeps the haematocrit under 45 percent and removes the need for phlebotomy in most patients (VERIFY).
- Am I a candidate for Rusfertide, and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
- How do the results of VERIFY apply to someone like me?Trial populations differ from individual patients; ask how closely you match.
Itching and burning extremities
- For my situation (itching and burning extremities), which of the standard options do you recommend and why?Guideline options include: Antihistamines, aspirin for erythromelalgia, interferon or ruxolitinib for severe aquagenic pruritus.
Post-PV myelofibrosis
- For my situation (post-pv myelofibrosis), which of the standard options do you recommend and why?Guideline options include: Managed as myelofibrosis: JAK inhibitors for spleen and symptoms, momelotinib for anaemia, allogeneic stem cell transplant for fit higher-risk patients.
- Am I a candidate for Ruxolitinib, Momelotinib, and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
Any stage
- Are there clinical trials I could join, for example of Givinostat, Bomedemstat, Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera, Clearing the JAK2 clone in polycythaemia vera: interferon plus mutant-selective inhibitors as a route to treatment-free remission?Trials are how the next standard of care is set; asking early keeps options open.
- Would a second opinion at a high-volume centre change anything, and can you help arrange it?Rare or high-stakes decisions benefit from a centre that treats many similar patients.
- What supportive care (symptom control, nutrition, exercise, mental health, financial help) is available from the start?Supportive care improves quality of life and helps patients complete treatment.
- I read that “No treatment has yet been shown to prevent progression to myelofibrosis or leukaemia; interferon's molecular responses are the strongest hint”. How does that affect my plan?Open problems are where trials and second opinions matter most.
- I read that “Risk stratification still rests on age and clot history; leukocyte count, allele burden and additional mutations are not yet built into treatment decisions”. How does that affect my plan?Open problems are where trials and second opinions matter most.
Trials open now for this cancer in OnCo, largest phase first. Joining a trial is a decision like any other: ask what the comparison arm is, whether a placebo is used, and what happens if you leave. The cancer page searches ClinicalTrials.gov live for more.
Much of what helps in the first weeks is free if you know to ask: testing, helplines, rides and lodging, second opinions, trial travel.
- Polycythaemia vera (PV): the full pagePolycythaemia vera is a slow blood cancer in which a single faulty gene, JAK2, makes the bone marrow produce too many red cells. Thick blood causes clots, so treatment thins it (blood removal, aspirin) and, for higher-risk patients, calms the marrow with hydroxyurea, interferon or ruxolitinib; a hepcidin mimic, rusfertide, now controls red cell counts without regular blood removal.
- One-page appointment sheetYour questions, the words you may hear, what to bring, and space for the answers. Print it.
- Treatment sequencingWhich treatment tends to follow which, line by line.
- NavigatorStandard of care for your stage, what you have tried, and trials near you.
- Phlebotomy (venesection): Removing about a pint of blood through a vein, as in a blood donation, to bring the red cell count down.
- Haematocrit: The share of blood volume made up of red cells.
- Hepcidin: The liver hormone that controls how much iron the body absorbs and releases.
- Erythrocytosis (primary vs secondary): Too many red cells.
- Aquagenic pruritus: Intense itching, prickling or burning of the skin within minutes of contact with water, typically after a shower.
- JAK2 V617F: A single letter change in the JAK2 gene that jams the growth signal for blood cells in the on position.
- Post-PV myelofibrosis (spent phase): The late stage some people with polycythaemia vera reach after many years, when the marrow scars over, the red count falls and the spleen swells.
- Erythromelalgia: Burning pain, redness and heat in the hands or feet, brought on by warmth.
Every term links to the glossary.